FDA Approves Mitapivat for Anemia in Thalassemia Patients 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
 - EconoTimes)
NEW YORK, July 14, 2017 -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Neurotrope, Inc. (NASDAQ:NTRP) who purchased shares between January 7, 2016, and April 28, 2017. The action, which was filed in the U.S. District Court for the Southern District of New York, alleges that the Company violated federal securities laws.
The complaint alleges that throughout the Class Period Neurotrope issued materially false and misleading statements and/or failed to disclose material information concerning the efficacy of its lead product candidate, Bryostatin-1. On May 1, 2017, Neurotrope issued a press release announcing “positive top-line results” of the pivotal Phase 2b trials of Bryostatin-1, noting “improvement in patients with moderate to severe Alzheimer’s disease.” However, the underlying trial data contradicts these representations, as the top-line data relating to the 20 microgram dose of Bryostatin-1 failed to produce results that were statistically significant. In addition, Neurotrope failed to disclose statements regarding the efficacy of the 40 microgram dose with regard to its primary and secondary endpoints. Upon this news, shares of Neurotrope fell from a close of $18.81 on April 28, 2017, to a close of $6.97 per share on May 1, 2017.
Shareholders have until July 17, 2017 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sa/neurotrope-inc?wire=3.
Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Joseph Klein, Esq. Empire State Building 350 Fifth Avenue 59th Floor New York, NY 10118 Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com
